|
| 多西紫杉醇联合顺铂治疗晚期胃癌临床观察 |
| Clinical Observation of Docetaxel plus Cisplatin in the Treatment of Advanced Gastric Cancer |
| 投稿时间：2005-12-05 |
| DOI： |
| 中文关键词: 多西紫杉醇 顺铂 胃癌/化疗 |
| 英文关键词:Docetaxel Cisplatin Gastric cancer Chemotherapy |
| 基金项目: |
| 于佩瑶 方凤奇 刘基巍 |
| 大连医科大学附属第一医院肿瘤科,辽宁大连116011 |
| 摘要点击次数: 1671 |
| 全文下载次数: 113 |
| 中文摘要: |
| 目的：评价多西紫杉醇（Doeetaxel）联合顺铂化疗方案，治疗晚期胃癌的临床疗效和毒性反应。方法：对30例晚期胃癌患者用多西紫杉醇联合顺铂化疗方案治疗78周期。结果：可评价疗效者30例，无完全缓解（CR）、部分缓解（PR）者10例（33．3％），稳定（SD）15例（50．0％），进展（PD）5例（16．7％），总有效率（CR＋PR）33．3％。临床受益率73．3％。肿瘤中位进展期5．6个月，中位生存期9．7个月。主要不良反应：WBC减少27例（90.0％），脱发26例（86．7％），恶心、呕吐22例（73．3％）等，无治疗相关性死亡。结论：多西紫杉醇联合顺铂化疗方案治疗晚期胃癌患者有效，临床缓解率较高，不良反应可耐受，可作为难治或复发的晚期胃癌的治疗方案。 |
| 英文摘要: |
| Objective:To evaluate the efficacy and toxicity of docetaxel plus cisplatin in the treatment of advanced gastric cancer. Method: 30 patients with advanced gastric cancer were enrolled in the chemotherapy regimen of docetaxel plus cisplatin for 78 cycles. Result:30 cases were valuable. No patients achieved CR; 10 achieved PR(33. 5% ) ; 15 , SD(50.0% ) and 5, PD( 16.7% ). The overall response rate (CR + PR) was 33. 3% , the clinical benefit percentage was 73. 3% , the median time to progression (TTP) was 5.6 months, and the median overall survival was 9. 7 months. The major side effects included leukopenia 90.0% (27/30) , alopecia 86.7% (26/30) , nausea and vomiting 73.3% (22/ 30). There were no treatment -related deaths among the patients. Conclusion:This study shows that the regimen of docetaxel plus cisplatin is effective, the clinical response rate, high and the adverse drug reaction, tolerable in advanced gastric cancer. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
